AP Photo/Mark Lennihan

The Senate has passed Sen. Ron Johnson's "right to try" bill, which would expand terminally ill patients' access to treatments that haven't yet been approved by the FDA. The bill passed by unanimous consent, and should help clear the way to vote on a larger FDA bill before senators break for the August recess.

Why it matters: On its face, right-to-try sounds simple enough: Why not let patients who are already dying, who have already tried everything else, take a shot at an unproven therapy? But the risk with unproven drugs isn't only that they might be ineffective — they also can carry side effects that might make patients' suffering worse. Regulators have also worried about maintaining the integrity of controlled clinical trials.

To address some of those concerns, the Senate bill says the FDA can't use data from right-to-try patients in its product reviews. The bill also wouldn't force drug makers to make their unproven products available — it simply says the federal government can't stand in the way of that transaction.

Go deeper

Updated 28 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Economy: Why the stimulus delay isn't a crisis (yet).
  3. Health: The pandemic is getting worse again New York reports most cases since MayMany U.S. coronavirus deaths were avoidable.
  4. Education: Boston and Chicago send students back home for online learning.
  5. World: Spain becomes first nation in Western Europe to exceed 1 million cases — France becomes the second.

Biden says he will appoint commission on Supreme Court reform

Photo: Chip Somodevilla/Getty Images

Joe Biden told CBS' "60 Minutes" this week that if elected, he would put together a bipartisan commission to study the federal court system and make recommendations for reform.

Why it matters: Biden has come under pressure to clarify his position on court packing after some Democrats suggested expanding the court if Senate Republicans confirm President Trump's Supreme Court nominee Amy Coney Barrett.

Dion Rabouin, author of Markets
59 mins ago - Economy & Business

Wall Street still prefers bonds

Illustration: Aïda Amer/Axios. Photo: Sunset Boulevard/Getty Contributor

Investors' return on U.S. corporate bonds has been falling since its August peak, but buying has only accelerated, especially in investment grade bonds that are offering historically low yields.

The state of play: Since hitting its 2020 high on Aug. 4, the benchmark Bloomberg Barclays U.S. bond aggregate has delivered a -2.2% return. (For comparison, the S&P 500 has gained 3.9% during the same time period.)

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!